IO Biotech, Inc. (IOBT)
NASDAQ: IOBT · Real-Time Price · USD
1.180
-0.020 (-1.67%)
At close: Nov 4, 2024, 4:00 PM
1.190
+0.010 (0.85%)
After-hours: Nov 4, 2024, 4:36 PM EST

Company Description

IO Biotech, Inc., a clinical-stage biopharmaceutical company, develops immune-modulating therapeutic cancer vaccines based on the T-win technology platform.

The company’s lead product candidate, IO102-IO103, which is designed to target immunosuppressive mechanisms mediated by Indoleamine 2,3-dehydrogenase (IDO), and programmed death-ligand (PD-L1) that is in phase 3 clinical trial to treat melanoma, as well as in phase 2 clinical trial to treat lung, head and neck, bladder, and melanoma cancer.

It also develops IO112, a product candidate that contains a single Arginase 1-derived peptide designed to target T cells that recognize epitopes derived from Arginase 1 for the treatment of cancers.

The company was incorporated in 2014 and is based in Copenhagen, Denmark.

IO Biotech, Inc.
IO Biotech logo
Country Denmark
Founded 2014
IPO Date Nov 5, 2021
Industry Biotechnology
Sector Healthcare
Employees 68
CEO Mai-Britt Zocca

Contact Details

Address:
Ole Maaløes Vej 3, Copenhagen N
Copenhagen, 2200
Denmark
Phone 45 70 70 29 80
Website iobiotech.com

Stock Details

Ticker Symbol IOBT
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
IPO Price $14.00
CIK Code 0001865494
CUSIP Number 449778109
ISIN Number US4497781090
Employer ID 87-0909276
SIC Code 2834

Key Executives

Name Position
Dr. Mai-Britt Zocca Ph.D. Founder, President, Chief Executive Officer, Principal Financial Officer and Director
Devin Whittemore Smith Secretary, General Counsel and Chief Compliance Officer
Dr. Qasim Iftikhar Ahmad M.D. Chief Medical Officer
Prof. Inge Marie Svane M.D., Ph.D. Founder and Clinical Advisor
Prof. Mads Hald Andersen M.D., Ph.D. Co-Founder and Scientific Advisor
Anders Ljungqvist Founder
Prof. Per Thor Straten Founder
Amy B. Sullivan M.B.A. Chief Financial Officer
Eric Faulkner M.B.A. Chief Technical Officer
Daniel G. Mannix Ph.D. Senior Vice President of Regulatory Affairs

Latest SEC Filings

Date Type Title
Sep 17, 2024 SC 13D/A [Amend] General statement of acquisition of beneficial ownership
Sep 11, 2024 144 Filing
Aug 30, 2024 8-K Current Report
Aug 13, 2024 10-Q Quarterly Report
Aug 13, 2024 UPLOAD Filing
Aug 13, 2024 8-K Current Report
Jul 30, 2024 UPLOAD Filing
Jul 25, 2024 144 Filing
Jun 11, 2024 8-K Current Report
May 14, 2024 SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals